Insulet (NASDAQ:PODD) Posts Earnings Results, Beats Estimates By $0.15 EPS

Insulet (NASDAQ:PODD) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15, Zacks reports. Insulet had a return on equity of 27.98% and a net margin of 21.22%. Insulet updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Insulet Stock Performance

Shares of NASDAQ PODD traded up $4.61 during mid-day trading on Thursday, reaching $288.29. 839,596 shares of the company’s stock were exchanged, compared to its average volume of 548,065. Insulet has a 52 week low of $160.19 and a 52 week high of $289.46. The firm has a 50-day moving average price of $272.37 and a two-hundred day moving average price of $246.18. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market capitalization of $20.22 billion, a price-to-earnings ratio of 49.36, a price-to-earnings-growth ratio of 3.52 and a beta of 1.23.

Analyst Ratings Changes

Several brokerages have weighed in on PODD. Barclays lifted their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Citigroup increased their price target on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. TD Cowen lifted their price objective on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Morgan Stanley increased their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, BTIG Research boosted their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $277.13.

Insider Buying and Selling at Insulet

In related news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.